AZD8186 First Time In Patient Ascending Dose Study
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Castrate-resistant Prostate Cancer CRPC|Squamous Non-Small Cell Lung Cancer sqNSCLC|Triple Negative Breast Cancer TNBC
Interventions: DRUG: Part A: AZD8186 monotherapy|DRUG: Part B: AZD8186 monotherapy|DRUG: Part C1: Abiraterone acetate combination with AZD8186|DRUG: Part D1: AZD2014 combination with AZD8186|DRUG: Part D2 AZD2014 combination with AZD8186|DRUG: Part C2: Abiraterone acetate combination with AZD8186
Sponsor: AstraZeneca